Skip to main content
SpringerLink
Log in

Immuntherapeutika und Zytostatika

  • Chapter
Arzneiverordnungs-Report 2006

Auszug

Hauptgruppen der Immuntherapeutika sind Zytokine (Interferone, koloniestimulierende Faktoren) und Immunsuppressiva. Betainterferone werden in weiter steigendem Umfang zur Behandlung der multiplen Sklerose eingesetzt, Alfainterferone vor allem bei der Hepatitis C. Hauptindikation der Immunsuppressiva ist die Prophylaxe von Abstoßungsreaktionen bei transplantierten Patienten.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • American Cancer Society (2002): Complementary and Alternative Cancer Methods Handbook. American Cancer Society.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (1996): Wie verträglich sind Echinacea-haltige Präparate? Dtsch Ärztebl 93: A–2723.

    Google Scholar 

  • Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J (2003): Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatol 38: 645–652.

    Article  CAS  Google Scholar 

  • Dold U, Edler L, Mäurer HC et al. (1991): Krebszusatztherapie beim fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom. Thieme, Stuttgart.

    Google Scholar 

  • Dunn CJ, Goa KL (2000): Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Drugs 59: 681–717.

    Article  PubMed  CAS  Google Scholar 

  • Ernst E (2001): The desktop guide to complementary and alternative medicine an evidence-based approach. Mosby, Hartcourt.

    Google Scholar 

  • Ernst E (2005): Commentary. FACT 10: 21–22.

    Article  Google Scholar 

  • Ernst E, Schmidt K, Steuer-Vogt MK (2003): Mistletoe for cancer? A systematic review of ranomised clinical trials. Int J Cancer 107: 262–267.

    Article  PubMed  CAS  Google Scholar 

  • Goodin DS (2001): Interferon-β therapy in multiple sclerosis: evidence for a clinically relevant dose response. Drugs 61: 1693–1703.

    Article  PubMed  CAS  Google Scholar 

  • Hohenberger P, Reichardt P, Stroszczynski C, Schneider U, Hossfeld DK (2003): Gastrointestinale Stromatumoren — Tumorentität und Therapie mit Imatinib. Dtsch Ärztebl 100: A1612–A1618.

    Google Scholar 

  • Kienle GS, Berrino F, Büssing A, Portalupi E, Rosenzweig S, Kienle H (2003): Mistletoe in cancer. A systematic review on controlled clinical trials. Eur J Med Res 8: 109–119.

    PubMed  CAS  Google Scholar 

  • Kienle GS, Kiene H (2004): Klinische Studien zur Misteltherapie onkologischer Erkrankungen. Dtsch Zeitschr Onkol 36: 17–24.

    Google Scholar 

  • Kleeberg UR, Suciu S, Bröcker EB, Ruiter DJ, Chartier C, Liénard D, Marsden J, Schadendorf D, Eggermont AM; EORTC Melanoma Group in cooperation with the German Cancer Society (DKG) (2004): Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-α2b versus rIFN-γ versus ISCADOR® versus observation after surgery in melanoma patients with either high-risk primary (thickness > 3 mm) or regional lymph node metastasis. Eur J Cancer 40: 390–402.

    Article  PubMed  CAS  Google Scholar 

  • Munari L, Lovati R, Boiko A (2004): Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev. 2004;(1):CD004678.

    Google Scholar 

  • Peggs K, Mackinnon S (2003): Imatinib Mesylate — The new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 348: 1048–1050.

    Article  PubMed  Google Scholar 

  • Rieckmann P, O’Connor P, Francis GS, Wetherill G, Alteri E (2004): Haematological effects of interferon-β-1a (Rebif®) therapy in multiple sclerosis. Drug Safety 27: 745–756.

    Article  PubMed  CAS  Google Scholar 

  • Scheer R, Bauer R, Becker H, Berg PA, Fintelmann V (2001): Vorwort S.V. In: Scheer R. et al. (Hrsg.): Die Mistel in der Tumortherapie, Grundlagenforschung und Klinik, KVC, Essen.

    Google Scholar 

  • Steuer-Vogt MK, Bonkowsky V, Ambrosch P, Scholz M, Neiß A, Strutz J, Hennig M, Lenarz T, Arnold W (2001): The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 37: 23–31.

    Article  PubMed  CAS  Google Scholar 

  • Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005): Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987–996.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Deutsches Krebsforschungszentrum, Abt. Perinatale Toxikologie, Im Neuenheimer Feld 280, 69120, Heidelberg

    Prof. Dr.med. W. Jens Zeller

Authors
  1. Prof. Dr.med. W. Jens Zeller
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Zeller, W.J. (2007). Immuntherapeutika und Zytostatika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2006. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-34370-7_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-34370-7_31

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-34369-1

  • Online ISBN: 978-3-540-34370-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation